[Corticosteroids in the management of advanced prostate cancer]. / Kortikoide im Management des fortgeschrittenen Prostatakarzinoms.
Urologe A
; 56(2): 217-223, 2017 Feb.
Article
en De
| MEDLINE
| ID: mdl-27878318
ABSTRACT
Corticosteroids have been widely used for decades in cancer therapy, predominantly due to their anti-inflammatory activity. In the treatment of metastatic castration-resistant prostate cancer (mCRPC), corticosteroids play an important role both in the management of tumor-related symptoms, especially bone metastasis-related pain, and as concomitant treatment to counteract side effects associated with approved active prostatic anticancer agents such as docetaxel, cabazitaxel, and abiraterone acetate. In association with abiraterone acetate, low-dose corticosteroids (prednisone or prednisolone) reduce the mineralocorticoid side effects of abiraterone. In addition, corticosteroids may exert direct antitumoral activities, resulting in PSA decline.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Cuidados Paliativos
/
Neoplasias Óseas
/
Corticoesteroides
/
Neoplasias de la Próstata Resistentes a la Castración
/
Antineoplásicos
Límite:
Humans
/
Male
Idioma:
De
Año:
2017
Tipo del documento:
Article